Pharmafile Logo

payer survey

Bayer symbol

Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

Bayer and Loxo hopeful about novel biomarker-led cancer treatment

Improving NHS sustainability through service redesign partnerships and effective communications

With year-on-year increases in demand and the imperative to reduce its deficits, the NHS must look beyond merely doing more of the same if it is to become sustainable. Never...

- PMLiVE

Improving childhood cancer survival rates in developing countries

IntroductionOne of the remarkable success stories in cancer care has been the increase in the long-term survival of children with leukaemia and solid tumours from almost nil to 75-80% cure...

NHS collaborates with VisualDX

CCGs will now have access to diagnostic clinical decision support resource

- PMLiVE

Real-world data finds patients feel better on Entresto, says Novartis

Patients on Entresto reported an “early, statistically significant improvement in health status”

- PMLiVE

Pharma sees European generics export plan as anti-innovation

EFPIA condemns plans - but European Commission says changes would create jobs in Europe

- PMLiVE

Daily Brief: Italy in turmoil, Pharma attacks Europe’s generics move and more

A rapid round up of news from pharma, biotech and healthcare

- PMLiVE

Safety scuppers combo trials with J&J/Genmab’s Darzalex

Studies revealed a “numerical increase” in patient deaths when Darzalex was combined with Roche’s Tecentriq

- PMLiVE

Transparency and accountability: tackling opacity and blame head-on

Delivering effective, code-compliant, transparent experiences and communications

- PMLiVE

Translating data to create a meaningful story

Ada Lovelace saw the true value of data, becoming obsessed with the Difference Engine, the first automatic computing engine designed by pioneer Charles Babbage in 1833. Ada was desperate to...

- PMLiVE

Daily Brief: GDPR and NHS Opt Out Day, BioMarin’s new rare disease approval and more

It's not just the GDPR's big day, plus news from Medigene and Pfizer

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links